Pharmaceutical & BioTech
Discover all our Pharmaceutical & BioTech services
Drug Development
Regulatory Affairs
Market Access
Pharmacovigilance
Quality & Compliance
Accelerating ODD and Approval
Client Profile
A fast-growing pharmaceutical company focused on rare diseases.
Executive Summary
- RPN aided in securing orphan drug designation and subsequent approval for a novel treatment for a rare metabolic disorder.
- Faced challenges with proving significant benefit over existing treatments, navigating orphan drug regulations, and expedited review processes.
- Delivered a strategic regulatory approach, expert dossier compilation, and continuous liaison with regulatory authorities, culminating in successful approval.
Challenges
The first step was demonstrating the significant benefit of the new treatment over existing therapies to meet the criteria for orphan drug designation. RPN supported the client in navigating the complex orphan drug regulatory framework and expedited review pathways.
Solutions
RPN conducted a comparative analysis of existing treatments to clearly articulate the novel treatment’s benefits and fulfill orphan drug criteria. The development of a compelling regulatory strategy leveraged on RPN’s expertise in rare diseases. RPN also ensured continuous and effective communication with regulatory authorities to navigate the expedited review process smoothly and address any queries promptly.
Results
The product successfully obtained the orphan drug designation thus opening the door to the free Scientific Advice procedure and other significant incentives. This set a precedent for future orphan drug applications, enhancing the client’s portfolio and expertise in rare diseases.